Abbott Laboratories (ABT) Total Current Liabilities (2009 - 2026)

Abbott Laboratories has reported Total Current Liabilities for 18 years, with the latest figure at $17.8 billion in Q2 2026.

• Quarterly Total Current Liabilities rose 32.55% year-over-year to $17.8 billion in Q2 2026, while the trailing twelve-month figure through Jun 2026 was $17.8 billion (up 32.55% YoY) and the FY2025 annual result came in at $16.5 billion, up 16.52% from the prior year.
• Total Current Liabilities retreated to $17.8 billion in Q2 2026 per ABT's latest filing, from $18.4 billion in the prior quarter.
• Over five years, Total Current Liabilities peaked at $18.4 billion in Q1 2026 and troughed at $12.4 billion in Q2 2022.
• A 5-year average of $14.5 billion and a median of $14.1 billion in 2024 frame the typical range for Total Current Liabilities.
• The sharpest annual moves came in 2023 and 2026: Total Current Liabilities decreased 10.64% in 2023, then soared 41.32% in 2026.
• Over 5 years, Total Current Liabilities stood at $15.5 billion in 2022, then slipped by 10.64% to $13.8 billion in 2023, then gained by 2.28% to $14.2 billion in 2024, then increased by 16.52% to $16.5 billion in 2025, then rose by 7.99% to $17.8 billion in 2026.
• According to Business Quant data, Total Current Liabilities over the past three periods registered $17.8 billion, $18.4 billion, and $16.5 billion for Q2 2026, Q1 2026, and Q4 2025 respectively.